Abstract 4361884: Improvement in Echocardiographic Measures of Diastolic Function Reflects Improved Exercise Performance in Obstructive Hypertrophic Cardiomyopathy: Insights From the SEQUOIA-HCM Trial
Abstract
Background: A hallmark feature of obstructive hypertrophic cardiomyopathy (oHCM) is impaired exercise capacity, which impacts quality of life and is a determinant of clinical outcomes. Understanding the mechanisms of exercise intolerance in oHCM remains essential to optimizing patient care. Research Question: This study addresses the relationships between changes in echocardiographic parameters and cardiopulmonary exercise testing (CPET) metrics in patients with oHCM from the SEQUOIA-HCM trial (NCT05186818). Methods: Patients enrolled in SEQUOIA-HCM with CPET data available at baseline and 24 weeks (w24) were included. Linear regression models were used to assess associations between changes in echo parameters and CPET metrics (peak oxygen uptake [pVO 2 ], minute ventilation [VE]/carbon dioxide output [VCO 2 ], composite z score, and anerobic threshold [AT]) from baseline to w24, adjusting for baseline values and clinical covariates. The composite z score was defined as the mean of standardized changes in pVO 2 and inverse VE/VCO 2 slope, with equal weighting for each component, and higher scores indicating favorable exercise performance. Cubic spline regression was used to model the relationship between changes in echo parameters and changes in CPET metrics. Results: A total of 282 patients (age 59±13years, 59% male, baseline pVO 2 18.5±4.5 mL/kg/min) were included. After adjustment, per each 5 mL/m 2 decrease in left atrial volume index (LAVi), there was a 0.3 mL/kg/min increase in pVO 2 (p=0.02), a 0.5 unit decrease in VE/VCO 2 slope (p=0.005), a 0.07 unit increase in the composite z score (p=0.001), and a 9.5 mL/min increase in AT (p=0.05) ( Table 1 ). Improvement in measures of diastolic function (lateral e’ and E/e’) demonstrated highly significant association with improvements in both pVO 2 and the composite z score (p<0.001 for both), and modest correlation with improved AT. Decreases in inferolateral wall thickness were associated with improvements in all CPET measures except AT. Cubic spline curves illustrate the relationships between changes in LAVi, lateral E/e’, and pVO 2 ( Fig 1 ). Conclusions: Aficamten treatment resulted in the improvement of measures of diastolic function, including E/e’, along with evidence of LA remodeling, both of which were associated with enhanced exercise capacity. These findings highlight diastolic dysfunction as a key pathophysiologic feature in oHCM and identify modifiable metrics that may aid in monitoring therapeutic response.
Article Details
Authors (17)
Henri Lu
Lausanne University Hospital, Lausanne, Switzerland
Nicole Bart
ST VINCENTS HOSPITAL, Sydney, New South Wales, Australia
Brian Claggett
Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston
Theodore Abraham
Department of Cardiology, University of, California, San Francisco, San Francisco
Caroline Coats
University og Glasgow, Glasgow, United Kingdom
Matthew Lee
Gregory Lewis
Massachusetts General Hospital, Boston, Massachusetts, United States
Martin maron
Lahey Hospital, Burlington, Massachusetts, United States
Ahmad Masri
Oregon Health and Science University, Portland
Iacopo Olivotto
Department of Cardiology, Meyer Children’s Hospital, IRCCS, Florence, Italy
Daniel Jacoby
Cytokinetics Inc., South San Francisco, California, United States
Stephen Heitner
Cytokinetics Inc., South San Francisco, California, United States
Stuart Kupfer
Cytokinetics, South San Francisco, CA
Fady Malik
Cytokinetics Inc., South San Francisco, California, United States
Amy Wohltman
Cytokinetics, South San Francisco, CA
Scott Solomon
Brigham and Women's Hospital, Boston, Massachusetts, United States
Sheila Hegde
The University of Texas Southwestern Medical Center, Dallas, Texas, United States